Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 46 Parkinson's papers of 289 | 0.49 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8687
Sealed predictions
- SLC20A2 in dopamine neurons, braak-0.36 (p 0.344) → -0.69 (p 0.041)receipt 8693
Swarm cases
receipt 8693: SLC20A2 in dopamine neurons, braak
- power
- full sample -0.51 (p 0.031, n 18), 95% CI -0.79 to -0.06. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.49 (p 0.040, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.028, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.44, sign flips 0; without severely affected donors -0.51 (p 0.031, n 18). robust.
- cell type
- strongest in astrocytes: -0.69 (p 0.0015, n 18) vs -0.51 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC20A2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SLC20A2 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.25 p 0.374 (needs p < 2.5e-4)
Receipts
loading the receipts